Durable efficacy and manageable long-term safety of lisocabtagene maraleucel for 3L+ FL: 3-year update from TRANSCEND FL.
Liso-cel provides durable remission with 97% response rate and 86% overall survival at 3 years in patients with relapsed/refractory 3L+ follicular lymphoma.
- Why it matters: Long-term data are crucial to confirm the sustained efficacy and safety of CAR T-cell therapy in high-risk lymphoma patients, addressing concerns about late toxicities and remission durability.
- What they did: The study analyzed 107 patients with relapsed/refractory 3L+ FL treated with liso-cel, with a median follow-up of 41.5 months, assessing response rates, survival, and safety over three years.
- The result: Results showed high and durable response rates, with 70% maintaining response at 36 months, and a manageable safety profile characterized by decreasing severe cytopenias and low infection rates, supporting long-term use.